文献速递药物不良反应与药物警戒

非甾体雄激素受体拮抗剂的分子结构、药理学与疑似不良反应的关联

The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United Kingdom.
PubMed 文献 · Br J Clin Pharmacol · 2026-04-29

本研究旨在探讨英国已上市非甾体雄激素受体拮抗剂(NSARA)的疑似不良反应谱与其化学性质及脱靶多药理学之间的潜在联系。恩扎卢胺和阿帕他胺的GABA受体及hERG抑制可能分别与神经系统疾病和心律失常相关。

要点

  • 恩扎卢胺疑似ADR最多(n=1091),其次为比卡鲁胺(n=738)。
  • 恩扎卢胺抑制GABA受体(IC50=2.6 μM)与神经系统疾病ADR相关。
  • 达罗他胺与5-HT(SERT)转运体相互作用可能影响心脏和肝胆ADR。

核心结论

  • NSARA的疑似ADR谱与其独特化学性质及已知脱靶多药理学之间存在潜在关联。
  • 恩扎卢胺的GABA受体抑制与神经系统疾病相关,阿帕他胺的hERG抑制与心律失常相关。
  • 达罗他胺与SERT转运体相互作用可能影响心脏和肝胆系统ADR。

研究设计与样本

  • 从Electronic Medicines Compendium、FDA新药申请文件和ChEMBL数据库整理理化与多药理学数据。
  • 从英国MHRA黄卡自发报告系统整理疑似ADR和死亡报告。
  • 从OpenPrescribing和NHS Digital二级护理药品数据推算日剂量数。

主要发现

  • 恩扎卢胺疑似ADR为1091例,比卡鲁胺为738例。
  • 恩扎卢胺对GABA受体抑制的IC50=2.6 μM,Cmax=7.7 μM,游离Cmax=185-212 nM。
  • 神经系统疾病ADR共72例,占该SOC中所有NSARA ADR的67%。
  • 恩扎卢胺具有最多的脱靶药理学相互作用(n=4)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This work aimed to correlate potential links between the suspected adverse drug reaction (ADR) profile of licensed nonsteroidal androgen receptor antagonists (NSARA) with their unique chemical properties and known off-target polypharmacology. METHODS: Physicochemical and polypharmacology data were curated from the Electronic Medicines Compendium, FDA New Drug Applications documents, and ChEMBL database. Suspected ADRs and fatalities were curated from the United Kingdom Medicines and Healthcare products Regulatory Authority (MHRA) Yellow card spontaneous reporting scheme. The number of daily doses (dd) was extrapolated from OpenPrescribing and NHS Digital secondary care medicines data. RESULTS: A total of n = 2522 suspected ADRs were associated with 42 903 000 dd of NSARAs usage in the United Kingdom. The highest number of ADRs were associated with enzalutamide (n = 1091) and bicalutamide (n = 738). Enzalutamide was found to have the most off-target pharmacological interactions of the NSARAs studied (n = 4) including potent inhibition of γ-aminobutyric acid, GABA receptor (IC50 = 2.6 μM vs. Cmax = 7.7 μM and Cmax, unbound = 185-212 nM) associated with nervous system disorders (n = 72, accounting for 67% of all NSARA ADRs in this SOC). CONCLUSIONS: Suspected skin and subcutaneous ADRs approached statistical significance and were interrogated for chemical and pharmacological connections for the first time with the aid of matched molecular pair (MMP) analysis. A potential correlation to nervous system disorders and cardiac arrhythmia for the GABA and hERG inhibitors, enzalutamide and apalutamide, respectively was identified. Darolutamide's interaction with the 5-HT (SERT) transporter may influence ADRs associated with cardiac and hepatobiliary SOCs.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Dhillon S, Antolin AA, Jones AM, et al. The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United Kingdom. Br J Clin Pharmacol. 2026. PMID: 42057435. doi:10.1002/bcp.70569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。